Navigation Links
If oxygen becomes the undoing of proteins
Date:10/12/2011

red by the BMBF, it was possible to show the diverse phases of the inactivation process for the first time using the so-called X-ray absorption spectroscopy. The researchers used the synchroton radiation source Swiss Light Source in Switzerland for this specific type of measurement. It generates particularly strong rays, thus enabling the characterization of metal centers in proteins. Amongst other things, the scientists thus determined the chemical nature of the iron centers and the distance from the surrounding atoms using atomic resolution.

Inactivation in three phases

The team of researchers from Bochum and Berlin used a new experimental procedure. They initially brought the hydrogenase sample into contact with oxygen for a few seconds to minutes and finally for a couple of hours and then suppressed all proceeding reactions by deep-freezing it in liquid nitrogen. The subsequently gained spectroscopic data was used for the development of a model for a three-phase inactivation process. According to this model, an oxygen molecule initially binds to the di-iron center of the hydrogenase, which leads to the development of an aggressive oxygen species. In the subsequent phase, this attacks and modifies the four-iron center. During the final phase, further oxygen molecules bind and the entire complex disintegrates. "The entire process thus consists of a number of consecutive reactions that are distinctly separated in time", says Lambertz. "The velocity of the entire process is possibly dependent on the phase during which the aggressive oxygen species moves from the di-iron to the four-iron center. We are currently elaborating further experiments to investigate this."


'/>"/>
Contact: Camilla Lambertz
Camilla.Lambertz@rub.de
49-234-322-4496
Ruhr-University Bochum
Source:Eurekalert

Page: 1 2

Related biology technology :

1. Oxygen Healthcare (O2h) Announces Expanded Chemistry Collaboration With Heptares Therapeutics
2. Sangart, Inc. Reports Positive Phase IIa Data for Novel Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients
3. Dehaier Medical Systems Signs $1.6 Million Oxygen-Chip Sales Contract
4. Medical Simulation Corporation Partners with Hutchinson Technology in Training of Healthcare Professionals on Noninvasive Tissue Oxygenation Monitoring
5. Heptares Therapeutics Extends Multi-FTE Chemistry Collaboration With Oxygen Healthcare (O2h)
6. Oxygen Biotherapeutics, Inc. Outlines Plans for New Products During Investor Conference Presentation
7. Spectros Corp. Deep-Monitoring Continuum Noninvasive Cerebral Oxygenation Sensors
8. Oxygen Biotherapeutics, Inc. Expands Board of Directors
9. New Oxygen Biotherapeutics, Inc. Investor Presentation Available on Company Website
10. Oxygen Biotherapeutics, Inc. Seeks Shareholder Approval for Reverse Stock Split
11. Oxygen Biotherapeutics, Inc. to Present at Investment Conferences in New York and Zurich
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... , Dec. 22, 2014 /PRNewswire/ - RepliCel Life Sciences ... medicine company focused on the development of autologous cell ... of the University of Calgary in conjunction with co-authors ... which further validates the company,s ongoing clinical research using ... of pattern baldness. The paper entitled " ...
(Date:12/22/2014)... The American Journal of Hematology/Oncology, a ... editorials addressing developments and pathways related to oncological ... article exploring the role of follicle-stimulating hormone (FSH) ... prostate cancer. , The article references seminal ... there could be a connection to prostate cancer ...
(Date:12/19/2014)... (PRWEB) December 19, 2014 Charm Sciences ... test for the Detection of Aflatoxin M1 in raw ... receive independent third party validation. The peer reviewed report ... of the Institute for Agricultural and Fisheries Research (ILVO-T&V) ... , Aflatoxin B1, the most toxic aflatoxin and ...
(Date:12/19/2014)... , Dec. 19, 2014 Bina Technologies, Inc. ... announced today that they have been acquired by Roche ... is a privately held company that provides a big ... generation sequencing (NGS) data for the academic and translational ... Sequencing Unit, and will continue to focus on development ...
Breaking Biology Technology:Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4Charm Sciences Achieves Independent Validation of First 15 Minute Quantitative Screening Method for Aflatoxin M1 2Bina Technologies is acquired by Roche. 2Bina Technologies is acquired by Roche. 3
... Notification), Pathway for AppyScore(TM), the First Blood-based Screening and Triage Test ... ... AspenBio Pharma,Inc. (Nasdaq: APPY ) an emerging bio-pharmaceutical company ... humans, has,received an official response from the Food and Drug Administration ...
... Nov. 27 Xenome Ltd, a specialist,biopharmaceutical ... it has successfully raised US$10M of equity ... from Xenome,s major investor,Queensland BioCapital Funds (QBF), ... Amylin Pharmaceuticals Inc, a top tier USA ...
... 26 Biomoda, Inc. (OTC,Bulletin Board: BMOD) ( ... approved MicroCap Management as the,front-runner of its full ... plan that will provide a launch pad for ... of Biomoda,s Senior Executive,Officers., John Cousins, President ...
Cached Biology Technology:AspenBio Pharma Pursues FDA 510(k) Application Pathway for Appendicitis Blood Test 2AspenBio Pharma Pursues FDA 510(k) Application Pathway for Appendicitis Blood Test 3AspenBio Pharma Pursues FDA 510(k) Application Pathway for Appendicitis Blood Test 4Xenome Receives a Syndicated US$10 Million Equity Investment from Queensland BioCapital Fund, Amylin Pharmaceuticals and Innovis Investment Partners 2Xenome Receives a Syndicated US$10 Million Equity Investment from Queensland BioCapital Fund, Amylin Pharmaceuticals and Innovis Investment Partners 3Biomoda, Inc. Retains MicroCap Management, LLC as its Lead Corporate Communications and Broker Relations Firm. 2
(Date:12/17/2014)... Valencell, a leader in performance biometric data ... industry leaders such as Intel, Jabra, Atlas, and Scosche ... products. These products will be showcased at CES 2015, ... . "Our partners choose PerformTek ... – with the clinical data to back it up," ...
(Date:12/11/2014)... DUBLIN , Dec. 09, 2014 Research ... http://photos.prnewswire.com/prnh/20130307/600769 ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) ... Market in India 2015-2019" report to their ... in this market is the adoption of multimodal ... one characteristic of an individual for verification and ...
(Date:12/10/2014)... , Dec. 9, 2014  Wake Forest Baptist Medical Center ... for its School of Medicine. Funding for this $50 ... campaign that will be publicly launched next summer. ... in the former 60 series R.J. Reynolds Tobacco Company ... Construction will begin immediately with plans to be ready ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
... 2012 - Every process in a cell is affected ... the human body and their relationship to diseases is ... therapies. The Ontario Genomics Institute (OGI) is providing $100,000 ... University of Toronto (U of T),s Mammalian Membrane Two-Hybrid ...
... Predicting how atherosclerosis, osteoporosis or cancer will progress ... difficult. In a new study, researchers took another ... able to predict from a blood sample the ... diseasesa specific person would produce. This ...
... for medical and biological research, but are difficult to study ... from adults may provide a path to study stem cells ... JoVE ( Journal of Visualized Experiments ), details ... cells in the peripheral blood. The technique has been ...
Cached Biology News:Ontario Genomics Institute invests in validation of a novel protein interaction technology at U of T 2Researchers use blood testing to predict level of enzymes that facilitate disease progression 2Novel technique to produce stem cells from peripheral blood 2
... Microarrays designed for RNA aptamer screening ... flexible and powerful Paraflo microfluidic on-chip synthesis ... can be synthesized on-chip and LC Sciences ... These microarrays are available as part of ...
... LX80L is an extension of Parkers MX80 family ... compact cross-section. LX80L bolt hole patterns mimic the ... units and all accessory brackets to build multi-axis ... travel to 750 mm , Accelerations to 5 ...
... is compatible with BioTeks microplate washers, ... of use and walkaway automation are ... When used with the ELx405 washer ... Bio-Stacks small footprint fits easily in ...
... the use of small interfering RNA (siRNA) ... RNA interference (RNAi) pathway have generated tremendous ... fields. siRNA for experimental use can be ... and then transfected into the target cells ...
Biology Products: